Blum Robert I 4

What Happened
Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), disposed of 7,931 shares on 2026-03-09 at $60.72 per share, for a total value of about $481,570. The sale was a "sell-to-cover" tied to tax withholding obligations upon the vesting of restricted stock units (RSUs), so this is a routine tax-related disposition rather than an open-market cash-out for other purposes.

Key Details

• Transaction date: 2026-03-09; Price: $60.72 per share; Shares sold: 7,931; Gross value ≈ $481,570.
• Reason: Sell-to-cover to satisfy company tax withholding obligations upon RSU vesting (footnote F1).
• Holdings after the transaction: Not specified on the filing; some shares are reported as held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust (footnotes F2, F3), indicating indirect holdings.
• Filing: Reported on 2026-03-10 (filed one day after the transaction), which is timely under Form 4 reporting rules.

Context
Sell-to-cover transactions are common when executives receive vested equity and are required to satisfy tax withholding; they do not necessarily signal a change in the insider’s long-term view. This transaction is a disposition (code S) and not a purchase or option exercise, so it should be interpreted as a routine tax-driven sale rather than a directional bet on the stock.